nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—Vismodegib—skin cancer	0.804	1	CrCtD
Tolvaptan—ABCB1—Vismodegib—skin cancer	0.0304	0.21	CbGbCtD
Tolvaptan—CYP3A4—Temozolomide—skin cancer	0.0262	0.182	CbGbCtD
Tolvaptan—CYP3A4—Imiquimod—skin cancer	0.0262	0.182	CbGbCtD
Tolvaptan—CYP3A4—Vismodegib—skin cancer	0.0182	0.126	CbGbCtD
Tolvaptan—ABCB1—Dactinomycin—skin cancer	0.016	0.11	CbGbCtD
Tolvaptan—CYP3A4—Vemurafenib—skin cancer	0.0144	0.0995	CbGbCtD
Tolvaptan—ABCB1—Docetaxel—skin cancer	0.00824	0.057	CbGbCtD
Tolvaptan—CYP3A4—Docetaxel—skin cancer	0.00493	0.0341	CbGbCtD
Tolvaptan—Vismodegib—SHH—skin cancer	0.00242	0.635	CrCbGaD
Tolvaptan—Rash generalised—Vemurafenib—skin cancer	0.00167	0.0398	CcSEcCtD
Tolvaptan—Vismodegib—SMO—skin cancer	0.00139	0.365	CrCbGaD
Tolvaptan—AVPR2—Arf6 trafficking events—EXOC2—skin cancer	0.000847	0.144	CbGpPWpGaD
Tolvaptan—Hyponatraemia—Vismodegib—skin cancer	0.000836	0.02	CcSEcCtD
Tolvaptan—Colitis ischaemic—Docetaxel—skin cancer	0.000819	0.0196	CcSEcCtD
Tolvaptan—Dehydration—Vismodegib—skin cancer	0.000774	0.0185	CcSEcCtD
Tolvaptan—Breast disorder—Vismodegib—skin cancer	0.000752	0.018	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Vismodegib—skin cancer	0.00075	0.0179	CcSEcCtD
Tolvaptan—Disseminated intravascular coagulation—Docetaxel—skin cancer	0.000674	0.0161	CcSEcCtD
Tolvaptan—Deep vein thrombosis—Temozolomide—skin cancer	0.000595	0.0142	CcSEcCtD
Tolvaptan—Rash generalised—Docetaxel—skin cancer	0.000567	0.0135	CcSEcCtD
Tolvaptan—Connective tissue disorder—Vismodegib—skin cancer	0.000566	0.0135	CcSEcCtD
Tolvaptan—Prurigo—Docetaxel—skin cancer	0.000522	0.0125	CcSEcCtD
Tolvaptan—Malnutrition—Vismodegib—skin cancer	0.000501	0.012	CcSEcCtD
Tolvaptan—Dysgeusia—Vismodegib—skin cancer	0.000491	0.0117	CcSEcCtD
Tolvaptan—Vaginal haemorrhage—Temozolomide—skin cancer	0.000489	0.0117	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Imiquimod—skin cancer	0.000448	0.0107	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000424	0.0101	CcSEcCtD
Tolvaptan—Nervous system disorder—Vismodegib—skin cancer	0.000401	0.00958	CcSEcCtD
Tolvaptan—Skin disorder—Vismodegib—skin cancer	0.000397	0.00949	CcSEcCtD
Tolvaptan—Breast disorder—Imiquimod—skin cancer	0.000396	0.00946	CcSEcCtD
Tolvaptan—Deep vein thrombosis—Docetaxel—skin cancer	0.000396	0.00945	CcSEcCtD
Tolvaptan—Respiratory failure—Temozolomide—skin cancer	0.000369	0.0088	CcSEcCtD
Tolvaptan—AVPR1A—Peptide GPCRs—MC1R—skin cancer	0.000365	0.0622	CbGpPWpGaD
Tolvaptan—Pulmonary embolism—Temozolomide—skin cancer	0.000362	0.00864	CcSEcCtD
Tolvaptan—AVPR2—Peptide GPCRs—MC1R—skin cancer	0.000362	0.0617	CbGpPWpGaD
Tolvaptan—Decreased appetite—Vismodegib—skin cancer	0.000356	0.00849	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Vismodegib—skin cancer	0.000353	0.00843	CcSEcCtD
Tolvaptan—Constipation—Vismodegib—skin cancer	0.00035	0.00835	CcSEcCtD
Tolvaptan—Connective tissue disorder—Vemurafenib—skin cancer	0.00035	0.00835	CcSEcCtD
Tolvaptan—Cardiac disorder—Vemurafenib—skin cancer	0.00033	0.00788	CcSEcCtD
Tolvaptan—Angiopathy—Vemurafenib—skin cancer	0.000323	0.00771	CcSEcCtD
Tolvaptan—Mediastinal disorder—Vemurafenib—skin cancer	0.000321	0.00765	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Bleomycin—skin cancer	0.000318	0.00759	CcSEcCtD
Tolvaptan—Malnutrition—Vemurafenib—skin cancer	0.00031	0.00739	CcSEcCtD
Tolvaptan—Dysgeusia—Vemurafenib—skin cancer	0.000303	0.00724	CcSEcCtD
Tolvaptan—Urinary tract disorder—Imiquimod—skin cancer	0.0003	0.00715	CcSEcCtD
Tolvaptan—Connective tissue disorder—Imiquimod—skin cancer	0.000298	0.00712	CcSEcCtD
Tolvaptan—Urethral disorder—Imiquimod—skin cancer	0.000297	0.0071	CcSEcCtD
Tolvaptan—Asthenia—Vismodegib—skin cancer	0.000294	0.00701	CcSEcCtD
Tolvaptan—Pruritus—Vismodegib—skin cancer	0.00029	0.00691	CcSEcCtD
Tolvaptan—Diarrhoea—Vismodegib—skin cancer	0.00028	0.00668	CcSEcCtD
Tolvaptan—Thirst—Temozolomide—skin cancer	0.000276	0.00659	CcSEcCtD
Tolvaptan—Angiopathy—Imiquimod—skin cancer	0.000275	0.00657	CcSEcCtD
Tolvaptan—Immune system disorder—Imiquimod—skin cancer	0.000274	0.00654	CcSEcCtD
Tolvaptan—Mediastinal disorder—Imiquimod—skin cancer	0.000273	0.00653	CcSEcCtD
Tolvaptan—Malnutrition—Imiquimod—skin cancer	0.000264	0.00631	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000262	0.00625	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000262	0.00625	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Docetaxel—skin cancer	0.000255	0.00608	CcSEcCtD
Tolvaptan—Anaphylactic shock—Vemurafenib—skin cancer	0.000253	0.00603	CcSEcCtD
Tolvaptan—Nervous system disorder—Vemurafenib—skin cancer	0.000248	0.00592	CcSEcCtD
Tolvaptan—Skin disorder—Vemurafenib—skin cancer	0.000246	0.00586	CcSEcCtD
Tolvaptan—Respiratory failure—Docetaxel—skin cancer	0.000245	0.00585	CcSEcCtD
Tolvaptan—Ill-defined disorder—Imiquimod—skin cancer	0.000245	0.00585	CcSEcCtD
Tolvaptan—Dehydration—Temozolomide—skin cancer	0.000244	0.00584	CcSEcCtD
Tolvaptan—Nausea—Vismodegib—skin cancer	0.000243	0.0058	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.000242	0.00578	CcSEcCtD
Tolvaptan—Pulmonary embolism—Docetaxel—skin cancer	0.000241	0.00575	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—MC1R—skin cancer	0.000239	0.0409	CbGpPWpGaD
Tolvaptan—Malaise—Imiquimod—skin cancer	0.000238	0.00569	CcSEcCtD
Tolvaptan—Breast disorder—Temozolomide—skin cancer	0.000238	0.00567	CcSEcCtD
Tolvaptan—Syncope—Imiquimod—skin cancer	0.000237	0.00565	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000237	0.00565	CcSEcCtD
Tolvaptan—Loss of consciousness—Imiquimod—skin cancer	0.000232	0.00554	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000232	0.00553	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000223	0.00533	CcSEcCtD
Tolvaptan—Discomfort—Imiquimod—skin cancer	0.000222	0.0053	CcSEcCtD
Tolvaptan—Dry mouth—Imiquimod—skin cancer	0.00022	0.00525	CcSEcCtD
Tolvaptan—Decreased appetite—Vemurafenib—skin cancer	0.00022	0.00525	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000218	0.00521	CcSEcCtD
Tolvaptan—Constipation—Vemurafenib—skin cancer	0.000216	0.00516	CcSEcCtD
Tolvaptan—Shock—Imiquimod—skin cancer	0.000212	0.00506	CcSEcCtD
Tolvaptan—Nervous system disorder—Imiquimod—skin cancer	0.000211	0.00505	CcSEcCtD
Tolvaptan—Pollakiuria—Temozolomide—skin cancer	0.00021	0.00501	CcSEcCtD
Tolvaptan—Skin disorder—Imiquimod—skin cancer	0.000209	0.005	CcSEcCtD
Tolvaptan—Anorexia—Imiquimod—skin cancer	0.000206	0.00491	CcSEcCtD
Tolvaptan—Hyperglycaemia—Temozolomide—skin cancer	0.000205	0.00489	CcSEcCtD
Tolvaptan—Body temperature increased—Vemurafenib—skin cancer	0.0002	0.00477	CcSEcCtD
Tolvaptan—Decreased appetite—Imiquimod—skin cancer	0.000187	0.00447	CcSEcCtD
Tolvaptan—Hypersensitivity—Vemurafenib—skin cancer	0.000186	0.00445	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Imiquimod—skin cancer	0.000186	0.00444	CcSEcCtD
Tolvaptan—Renal impairment—Docetaxel—skin cancer	0.000184	0.00438	CcSEcCtD
Tolvaptan—Asthenia—Vemurafenib—skin cancer	0.000181	0.00433	CcSEcCtD
Tolvaptan—Urinary tract disorder—Temozolomide—skin cancer	0.00018	0.00429	CcSEcCtD
Tolvaptan—Pruritus—Vemurafenib—skin cancer	0.000179	0.00427	CcSEcCtD
Tolvaptan—Connective tissue disorder—Temozolomide—skin cancer	0.000179	0.00427	CcSEcCtD
Tolvaptan—Urethral disorder—Temozolomide—skin cancer	0.000178	0.00426	CcSEcCtD
Tolvaptan—Feeling abnormal—Imiquimod—skin cancer	0.000178	0.00424	CcSEcCtD
Tolvaptan—Hyponatraemia—Docetaxel—skin cancer	0.000176	0.00419	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000175	0.00417	CcSEcCtD
Tolvaptan—Ill-defined disorder—Bleomycin—skin cancer	0.000174	0.00416	CcSEcCtD
Tolvaptan—Diarrhoea—Vemurafenib—skin cancer	0.000173	0.00413	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—MC1R—skin cancer	0.000171	0.0292	CbGpPWpGaD
Tolvaptan—Body temperature increased—Imiquimod—skin cancer	0.00017	0.00407	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—MC1R—skin cancer	0.00017	0.029	CbGpPWpGaD
Tolvaptan—Malaise—Bleomycin—skin cancer	0.000169	0.00404	CcSEcCtD
Tolvaptan—Cardiac disorder—Temozolomide—skin cancer	0.000169	0.00403	CcSEcCtD
Tolvaptan—Dizziness—Vemurafenib—skin cancer	0.000167	0.00399	CcSEcCtD
Tolvaptan—Angiopathy—Temozolomide—skin cancer	0.000165	0.00394	CcSEcCtD
Tolvaptan—Immune system disorder—Temozolomide—skin cancer	0.000164	0.00392	CcSEcCtD
Tolvaptan—Mediastinal disorder—Temozolomide—skin cancer	0.000164	0.00391	CcSEcCtD
Tolvaptan—Dehydration—Docetaxel—skin cancer	0.000163	0.00388	CcSEcCtD
Tolvaptan—Ill-defined disorder—Dactinomycin—skin cancer	0.000162	0.00388	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Docetaxel—skin cancer	0.00016	0.00381	CcSEcCtD
Tolvaptan—Hypersensitivity—Imiquimod—skin cancer	0.000159	0.00379	CcSEcCtD
Tolvaptan—Headache—Vemurafenib—skin cancer	0.000158	0.00378	CcSEcCtD
Tolvaptan—Malnutrition—Temozolomide—skin cancer	0.000158	0.00378	CcSEcCtD
Tolvaptan—Breast disorder—Docetaxel—skin cancer	0.000158	0.00377	CcSEcCtD
Tolvaptan—Discomfort—Bleomycin—skin cancer	0.000158	0.00377	CcSEcCtD
Tolvaptan—Malaise—Dactinomycin—skin cancer	0.000158	0.00377	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—PTGER4—skin cancer	0.000157	0.0269	CbGpPWpGaD
Tolvaptan—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000157	0.00376	CcSEcCtD
Tolvaptan—Dysgeusia—Temozolomide—skin cancer	0.000155	0.0037	CcSEcCtD
Tolvaptan—Asthenia—Imiquimod—skin cancer	0.000155	0.00369	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000154	0.00368	CcSEcCtD
Tolvaptan—Anaphylactic shock—Bleomycin—skin cancer	0.000153	0.00366	CcSEcCtD
Tolvaptan—Pruritus—Imiquimod—skin cancer	0.000153	0.00364	CcSEcCtD
Tolvaptan—Nausea—Vemurafenib—skin cancer	0.00015	0.00358	CcSEcCtD
Tolvaptan—Diarrhoea—Imiquimod—skin cancer	0.000148	0.00352	CcSEcCtD
Tolvaptan—Discomfort—Dactinomycin—skin cancer	0.000147	0.00351	CcSEcCtD
Tolvaptan—Ill-defined disorder—Temozolomide—skin cancer	0.000147	0.00351	CcSEcCtD
Tolvaptan—Anorexia—Bleomycin—skin cancer	0.000146	0.00348	CcSEcCtD
Tolvaptan—Malaise—Temozolomide—skin cancer	0.000143	0.00341	CcSEcCtD
Tolvaptan—Dizziness—Imiquimod—skin cancer	0.000143	0.0034	CcSEcCtD
Tolvaptan—Anorexia—Dactinomycin—skin cancer	0.000136	0.00325	CcSEcCtD
Tolvaptan—Headache—Imiquimod—skin cancer	0.000135	0.00322	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000134	0.0229	CbGpPWpGaD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000134	0.00319	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000133	0.0227	CbGpPWpGaD
Tolvaptan—Discomfort—Temozolomide—skin cancer	0.000133	0.00318	CcSEcCtD
Tolvaptan—Decreased appetite—Bleomycin—skin cancer	0.000133	0.00318	CcSEcCtD
Tolvaptan—Renal failure—Docetaxel—skin cancer	0.000132	0.00316	CcSEcCtD
Tolvaptan—Dry mouth—Temozolomide—skin cancer	0.000132	0.00315	CcSEcCtD
Tolvaptan—Anaphylactic shock—Temozolomide—skin cancer	0.000129	0.00308	CcSEcCtD
Tolvaptan—Nausea—Imiquimod—skin cancer	0.000128	0.00306	CcSEcCtD
Tolvaptan—Nervous system disorder—Temozolomide—skin cancer	0.000127	0.00302	CcSEcCtD
Tolvaptan—Feeling abnormal—Bleomycin—skin cancer	0.000126	0.00301	CcSEcCtD
Tolvaptan—Skin disorder—Temozolomide—skin cancer	0.000125	0.003	CcSEcCtD
Tolvaptan—Decreased appetite—Dactinomycin—skin cancer	0.000124	0.00296	CcSEcCtD
Tolvaptan—Anorexia—Temozolomide—skin cancer	0.000123	0.00294	CcSEcCtD
Tolvaptan—Discomfort—Fluorouracil—skin cancer	0.000123	0.00293	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—PTCH2—skin cancer	0.000121	0.0207	CbGpPWpGaD
Tolvaptan—Body temperature increased—Bleomycin—skin cancer	0.000121	0.00289	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—PTCH2—skin cancer	0.00012	0.0205	CbGpPWpGaD
Tolvaptan—Urinary tract disorder—Docetaxel—skin cancer	0.000119	0.00285	CcSEcCtD
Tolvaptan—Anaphylactic shock—Fluorouracil—skin cancer	0.000119	0.00284	CcSEcCtD
Tolvaptan—Connective tissue disorder—Docetaxel—skin cancer	0.000119	0.00284	CcSEcCtD
Tolvaptan—Urethral disorder—Docetaxel—skin cancer	0.000119	0.00283	CcSEcCtD
Tolvaptan—Feeling abnormal—Dactinomycin—skin cancer	0.000118	0.00281	CcSEcCtD
Tolvaptan—Nervous system disorder—Fluorouracil—skin cancer	0.000117	0.00279	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000115	0.0196	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000114	0.0195	CbGpPWpGaD
Tolvaptan—Anorexia—Fluorouracil—skin cancer	0.000113	0.00271	CcSEcCtD
Tolvaptan—Body temperature increased—Dactinomycin—skin cancer	0.000113	0.0027	CcSEcCtD
Tolvaptan—Hypersensitivity—Bleomycin—skin cancer	0.000113	0.00269	CcSEcCtD
Tolvaptan—Decreased appetite—Temozolomide—skin cancer	0.000112	0.00268	CcSEcCtD
Tolvaptan—Cardiac disorder—Docetaxel—skin cancer	0.000112	0.00268	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Temozolomide—skin cancer	0.000112	0.00266	CcSEcCtD
Tolvaptan—Constipation—Temozolomide—skin cancer	0.00011	0.00264	CcSEcCtD
Tolvaptan—Asthenia—Bleomycin—skin cancer	0.00011	0.00262	CcSEcCtD
Tolvaptan—Angiopathy—Docetaxel—skin cancer	0.00011	0.00262	CcSEcCtD
Tolvaptan—Immune system disorder—Docetaxel—skin cancer	0.000109	0.00261	CcSEcCtD
Tolvaptan—Mediastinal disorder—Docetaxel—skin cancer	0.000109	0.0026	CcSEcCtD
Tolvaptan—Pruritus—Bleomycin—skin cancer	0.000108	0.00259	CcSEcCtD
Tolvaptan—Feeling abnormal—Temozolomide—skin cancer	0.000106	0.00254	CcSEcCtD
Tolvaptan—Malnutrition—Docetaxel—skin cancer	0.000105	0.00251	CcSEcCtD
Tolvaptan—Hypersensitivity—Dactinomycin—skin cancer	0.000105	0.00251	CcSEcCtD
Tolvaptan—Decreased appetite—Fluorouracil—skin cancer	0.000103	0.00247	CcSEcCtD
Tolvaptan—Dysgeusia—Docetaxel—skin cancer	0.000103	0.00246	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000103	0.00245	CcSEcCtD
Tolvaptan—Asthenia—Dactinomycin—skin cancer	0.000102	0.00245	CcSEcCtD
Tolvaptan—Body temperature increased—Temozolomide—skin cancer	0.000102	0.00244	CcSEcCtD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	9.83e-05	0.0168	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Fluorouracil—skin cancer	9.81e-05	0.00234	CcSEcCtD
Tolvaptan—Diarrhoea—Dactinomycin—skin cancer	9.77e-05	0.00233	CcSEcCtD
Tolvaptan—Hypersensitivity—Temozolomide—skin cancer	9.52e-05	0.00227	CcSEcCtD
Tolvaptan—Syncope—Docetaxel—skin cancer	9.44e-05	0.00225	CcSEcCtD
Tolvaptan—Body temperature increased—Fluorouracil—skin cancer	9.41e-05	0.00225	CcSEcCtD
Tolvaptan—Asthenia—Temozolomide—skin cancer	9.27e-05	0.00221	CcSEcCtD
Tolvaptan—Loss of consciousness—Docetaxel—skin cancer	9.25e-05	0.00221	CcSEcCtD
Tolvaptan—Pruritus—Temozolomide—skin cancer	9.14e-05	0.00218	CcSEcCtD
Tolvaptan—Nausea—Bleomycin—skin cancer	9.1e-05	0.00217	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	8.9e-05	0.00212	CcSEcCtD
Tolvaptan—Diarrhoea—Temozolomide—skin cancer	8.84e-05	0.00211	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	8.83e-05	0.0151	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Fluorouracil—skin cancer	8.77e-05	0.00209	CcSEcCtD
Tolvaptan—Dry mouth—Docetaxel—skin cancer	8.77e-05	0.00209	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	8.76e-05	0.0149	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—MC1R—skin cancer	8.76e-05	0.0149	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—MC1R—skin cancer	8.69e-05	0.0148	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Docetaxel—skin cancer	8.59e-05	0.00205	CcSEcCtD
Tolvaptan—Dizziness—Temozolomide—skin cancer	8.54e-05	0.00204	CcSEcCtD
Tolvaptan—Nausea—Dactinomycin—skin cancer	8.49e-05	0.00203	CcSEcCtD
Tolvaptan—Shock—Docetaxel—skin cancer	8.45e-05	0.00202	CcSEcCtD
Tolvaptan—Nervous system disorder—Docetaxel—skin cancer	8.43e-05	0.00201	CcSEcCtD
Tolvaptan—Pruritus—Fluorouracil—skin cancer	8.42e-05	0.00201	CcSEcCtD
Tolvaptan—Skin disorder—Docetaxel—skin cancer	8.35e-05	0.00199	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.3e-05	0.0142	CbGpPWpGaD
Tolvaptan—Anorexia—Docetaxel—skin cancer	8.19e-05	0.00195	CcSEcCtD
Tolvaptan—Diarrhoea—Fluorouracil—skin cancer	8.15e-05	0.00194	CcSEcCtD
Tolvaptan—Headache—Temozolomide—skin cancer	8.09e-05	0.00193	CcSEcCtD
Tolvaptan—Dizziness—Fluorouracil—skin cancer	7.87e-05	0.00188	CcSEcCtD
Tolvaptan—Nausea—Temozolomide—skin cancer	7.67e-05	0.00183	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	7.56e-05	0.0129	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RHOU—skin cancer	7.52e-05	0.0128	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	7.51e-05	0.0128	CbGpPWpGaD
Tolvaptan—Decreased appetite—Docetaxel—skin cancer	7.47e-05	0.00178	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—RHOU—skin cancer	7.47e-05	0.0127	CbGpPWpGaD
Tolvaptan—Headache—Fluorouracil—skin cancer	7.46e-05	0.00178	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Docetaxel—skin cancer	7.42e-05	0.00177	CcSEcCtD
Tolvaptan—Constipation—Docetaxel—skin cancer	7.35e-05	0.00175	CcSEcCtD
Tolvaptan—Feeling abnormal—Docetaxel—skin cancer	7.08e-05	0.00169	CcSEcCtD
Tolvaptan—Nausea—Fluorouracil—skin cancer	7.07e-05	0.00169	CcSEcCtD
Tolvaptan—Body temperature increased—Docetaxel—skin cancer	6.79e-05	0.00162	CcSEcCtD
Tolvaptan—Hypersensitivity—Docetaxel—skin cancer	6.33e-05	0.00151	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—SHH—skin cancer	6.24e-05	0.0106	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTCH2—skin cancer	6.22e-05	0.0106	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—SHH—skin cancer	6.2e-05	0.0106	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTCH2—skin cancer	6.17e-05	0.0105	CbGpPWpGaD
Tolvaptan—Asthenia—Docetaxel—skin cancer	6.16e-05	0.00147	CcSEcCtD
Tolvaptan—Pruritus—Docetaxel—skin cancer	6.08e-05	0.00145	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—PTCH1—skin cancer	5.92e-05	0.0101	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—SMO—skin cancer	5.92e-05	0.0101	CbGpPWpGaD
Tolvaptan—Diarrhoea—Docetaxel—skin cancer	5.88e-05	0.0014	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—SMO—skin cancer	5.87e-05	0.01	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—PTCH1—skin cancer	5.87e-05	0.01	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—PTGER4—skin cancer	5.76e-05	0.00982	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—PTGER4—skin cancer	5.72e-05	0.00975	CbGpPWpGaD
Tolvaptan—Dizziness—Docetaxel—skin cancer	5.68e-05	0.00136	CcSEcCtD
Tolvaptan—Headache—Docetaxel—skin cancer	5.38e-05	0.00128	CcSEcCtD
Tolvaptan—Nausea—Docetaxel—skin cancer	5.1e-05	0.00122	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—MC1R—skin cancer	4.95e-05	0.00844	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—MC1R—skin cancer	4.91e-05	0.00838	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—MC1R—skin cancer	4.49e-05	0.00767	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—MC1R—skin cancer	4.46e-05	0.00761	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTCH2—skin cancer	3.67e-05	0.00626	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTCH2—skin cancer	3.65e-05	0.00622	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PTGER4—skin cancer	3.25e-05	0.00555	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PTGER4—skin cancer	3.23e-05	0.00551	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—SHH—skin cancer	3.2e-05	0.00546	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—SHH—skin cancer	3.18e-05	0.00542	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTCH1—skin cancer	3.04e-05	0.00518	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—SMO—skin cancer	3.04e-05	0.00518	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTCH1—skin cancer	3.01e-05	0.00514	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—SMO—skin cancer	3.01e-05	0.00514	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	3e-05	0.00512	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTGER4—skin cancer	2.96e-05	0.00504	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTGER4—skin cancer	2.93e-05	0.00501	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	2.93e-05	0.005	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GLI2—skin cancer	2.78e-05	0.00475	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GLI2—skin cancer	2.76e-05	0.00471	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MC1R—skin cancer	2.65e-05	0.00453	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MC1R—skin cancer	2.64e-05	0.0045	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GLI1—skin cancer	2.62e-05	0.00446	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GLI1—skin cancer	2.6e-05	0.00443	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.58e-05	0.0044	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SUFU—skin cancer	2.48e-05	0.00423	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SUFU—skin cancer	2.46e-05	0.0042	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.3e-05	0.00393	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.19e-05	0.00374	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.18e-05	0.00372	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.1e-05	0.00358	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SHH—skin cancer	1.89e-05	0.00323	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RASA1—skin cancer	1.88e-05	0.00321	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SHH—skin cancer	1.88e-05	0.0032	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RASA1—skin cancer	1.87e-05	0.00318	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTCH1—skin cancer	1.79e-05	0.00306	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SMO—skin cancer	1.79e-05	0.00306	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SMO—skin cancer	1.78e-05	0.00304	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTCH1—skin cancer	1.78e-05	0.00304	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTGER4—skin cancer	1.75e-05	0.00298	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTGER4—skin cancer	1.73e-05	0.00296	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.58e-05	0.0027	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FOXO4—skin cancer	1.54e-05	0.00263	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FOXO4—skin cancer	1.53e-05	0.00261	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.12e-05	0.00191	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TERT—skin cancer	1.03e-05	0.00176	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TERT—skin cancer	1.02e-05	0.00174	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—NRAS—skin cancer	8.68e-06	0.00148	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—NRAS—skin cancer	8.62e-06	0.00147	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—BRAF—skin cancer	8.16e-06	0.00139	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—BRAF—skin cancer	8.1e-06	0.00138	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	8.01e-06	0.00137	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PLIN2—skin cancer	7.81e-06	0.00133	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—KRAS—skin cancer	7.47e-06	0.00127	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—KRAS—skin cancer	7.42e-06	0.00127	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—HRAS—skin cancer	6.35e-06	0.00108	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—HRAS—skin cancer	6.3e-06	0.00108	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CSPG4—skin cancer	6.29e-06	0.00107	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL6—skin cancer	6.08e-06	0.00104	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL6—skin cancer	6.03e-06	0.00103	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.37e-06	0.000915	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NRAS—skin cancer	5.13e-06	0.000875	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NRAS—skin cancer	5.09e-06	0.000868	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PLIN2—skin cancer	4.81e-06	0.000821	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.77e-06	0.000814	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KRAS—skin cancer	4.41e-06	0.000753	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KRAS—skin cancer	4.38e-06	0.000747	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ENO2—skin cancer	4.28e-06	0.00073	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TP53—skin cancer	3.92e-06	0.000669	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TP53—skin cancer	3.89e-06	0.000664	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CSPG4—skin cancer	3.88e-06	0.000662	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HRAS—skin cancer	3.75e-06	0.00064	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HRAS—skin cancer	3.72e-06	0.000635	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL6—skin cancer	3.59e-06	0.000612	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL6—skin cancer	3.56e-06	0.000608	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ENO2—skin cancer	2.64e-06	0.00045	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ERCC2—skin cancer	2.49e-06	0.000424	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ERCC2—skin cancer	1.53e-06	0.000261	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTGS2—skin cancer	1.49e-06	0.000254	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTGS2—skin cancer	9.18e-07	0.000157	CbGpPWpGaD
